Orchid Pharma Limited — Others, 11-11-2024: Statement of deviation(s) or variation(s) under Reg. 32

Orchid Pharma Limited's Board has conducted a meeting to approve the unaudited financial results for the quarter and half-year ended September 30, 2024. The company's standalone net sales stood at ₹22,269.86 crore, reflecting a robust growth when compared to ₹19,875.53 crore for the same quarter last year. The total income increased to ₹23,066.18 crore, while profit before tax reached ₹2,562.58 crore. These results indicate a positive trajectory for the company's operations, suggesting improved financial health. Investors may view this as a favorable signal, reflecting the company's strategic focus on growth and operational efficiency, alongside potential risks from ongoing financial consolidations.